United States - English - NLM (National Library of Medicine)

canton laboratories - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - naprosyn tablets, ec-naprosyn, and anaprox ds are indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis naprosyn tablets and anaprox ds are also indicated for: the relief of signs and symptoms of: - tendonitis - bursitis - acute gout the management of: - pain - primary dysmenorrhea naprosyn tablets, ec-naprosyn, and anaprox ds are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see warnings and precautions (5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1) ] risk summary use

United States - English - NLM (National Library of Medicine)

athena bioscience, llc - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naprosyn (naproxen) suspension is indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis - tendonitis - bursitis - acute gout the management of: - pain - primary dysmenorrhea naprosyn suspension is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see warnings and precautions (5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1 cardiovascular thrombotic events) ] risk summary use of nsaids, including naprosyn suspension, can cause premature closure of the fetal ductus arteriosus a

United States - English - NLM (National Library of Medicine)

genentech, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naprosyn, ec-naprosyn, anaprox, anaprox ds or naprosyn suspension and other treatment options before deciding to use naprosyn, ec-naprosyn, anaprox, anaprox ds or naprosyn suspension. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen as naprosyn, ec-naprosyn, anaprox, anaprox ds or naprosyn suspension is indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naprosyn suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient's weight. naproxen as naprosyn, anaprox, anaprox ds and naprosyn suspension is also indicated: - for relief of the signs and symptoms of tendonitis - for r

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - naproxen 1000mg - modified release tablet - 1000 mg - active: naproxen 1000mg excipient: hypromellose magnesium stearate purified water sunset yellow fcf - naprosyn sr is indicated for its anti-inflammatory and analgesic action in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and other musculoskeletal disorders,

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - naproxen 750mg - modified release tablet - 750 mg - active: naproxen 750mg excipient: hypromellose magnesium stearate purified water sunset yellow fcf - naprosyn sr is indicated for its anti-inflammatory and analgesic action in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and other musculoskeletal disorders,

United States - English - NLM (National Library of Medicine)

amphastar pharmaceuticals, inc. - cosyntropin (unii: 72yy86ea29) (cosyntropin - unii:72yy86ea29) - cosyntropin 0.25 mg in 1 ml - cortrosyn® (cosyntropin) for injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see dosage and administration section). severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. for this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. when presumptive adrenal insufficiency is diagnosed by a subnormal cortrosyn® test, further studies are indicated to determine if it is primary or secondary. primary adrenal insufficiency (addison’s disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. the production of adrenocortical hormones is deficient despite high acth levels (feedback mechanism). secondary or relative insufficiency arises as the result of defective production of acth leading in turn to disuse atrophy of the adrenal cortex. it is commonly seen, for example, as result of corticosteroid therapy, sheehan’s syndrome and pituitary tumors or ablation. the differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by acth whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with acth. patients selected for further study as the result of a subnormal cortrosyn® test should be given a 3 or 4 day course of treatment with repository corticotropin injection usp and then retested. suggested doses are 40 usp units twice daily for 4 days or 60 usp units twice daily for 3 days. under these conditions little or no increase in plasma cortisol levels will be seen in addison’s disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. the only contraindication to cortrosyn® (cosyntropin) for injection is a history of a previous adverse reaction to it.

Ireland - English - HPRA (Health Products Regulatory Authority)

atnahs pharma uk limited - naproxen - gastro-resistant tablet - 500 milligram(s) - propionic acid derivatives; naproxen - anti-inflammatory and antirheumatic products, non- steroids - naprosyn ec is indicated in adults and adolescents (16 years and above) for the treatment of rheumatoid arthritis, osteoarthrosis (degenerative arthritis), ankylosing spondylitis, acute gout, acute musculo-skeletal disorders (such as sprains and strains, direct trauma, lumbosacral pain, cervical spondylitis, tenosynovitis and fibrositis) and dysmenorrhoea.

Ireland - English - HPRA (Health Products Regulatory Authority)

atnahs pharma uk limited - naproxen - gastro-resistant tablet - 250 milligram(s) - propionic acid derivatives; naproxen - anti-inflammatory and antirheumatic products, non- steroids - naprosyn ec is indicated in adults and adolescents (16 years and above) for the treatment of rheumatoid arthritis, osteoarthrosis (degenerative arthritis), ankylosing spondylitis, acute gout, acute musculo-skeletal disorders (such as sprains and strains, direct trauma, lumbosacral pain, cervical spondylitis, tenosynovitis and fibrositis) and dysmenorrhoea.

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - cosyntropin (unii: 72yy86ea29) (cosyntropin - unii:72yy86ea29) - cosyntropin 0.25 mg in 1 ml - for diagnostic use only cortrosyn™ (cosyntropin) for injection is a sterile lyophilized powder in vials containing 0.25 mg of cortrosyn™ and 10 mg of mannitol to be reconstituted with 1 ml of 0.9% sodium chloride injection, usp. administration is by intravenous or intramuscular injection. cosyntropin is a 1 – 24 corticotropin, a synthetic subunit of acth. it is an open chain polypeptide containing, from the n terminus, the first 24 of the 39 amino acids of natural acth. the sequence of amino acids in the 1 – 24 compound is as follows:

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 250 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; iron oxide yellow; povidone; magnesium stearate - for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.